Retatrutide, developed by Soma Pharmaceuticals , is receiving considerable attention as a potential therapy for obesity control . This dual-action compound combines the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , designed to not only promote weight loss but also target u